MERSİN UNIVERSITY HOSPITAL
Slide background
Corporate

Department of Infectious Diseases


Publications in International Scientific Journals(last two years)

2020
4. Sayan, M.; özgüler, M.; Sarıgül yıldırım, F.; Yıldırmak, T.; Gündüz, A.; Dokuzoğuz, B.; çelen, M.; Inan, D.; Heper, Y. Molecular Identification of HIV-1 in the Presence of Hepatitis B Virus and Hepatitis C Virus Co-infections. GALENOS YAYINEVI, 2020, 37, 125-130.
http://dx.doi.org/10.4274/balkanmedj.galenos.2020.2019.5.89
3. Aygen, B.; Demirturk, N.; Yildiz, O.; Celen, M.; Celik, I.; Barut, S.; Ural, O.; Batirel, A. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. AVES PUBLISHING CO., 2020, 31, 305-317.
http://dx.doi.org/10.5152/TJG.2020.19197
2. Kurtaran, B.; Kuscu, F.; Korkmaz, P.; Ozdemir, B.; ınan, D.; Oztoprak, N.; Ozatag, D.; Daglı, O.; Birengel, S. A snapshot of geriatric infections in Turkey: ratio of geriatric inpatients in hospitals and evaluation of their infectious diseases: A multicenter point prevalence study. ELSEVIER BV, 2020, 100, 337-342.
http://dx.doi.org/10.1016/j.ijid.2020.08.046
1. Sayan, M.; Yıldırım, F.; Akhan, S.; Yıldırım, A.; şirin, G.; Cabalak, M.; Demir, M.; Can, S.; Ersöz, G. NS5A resistance – associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. ELSEVIER BV, 2020, 95, 84-89.
http://dx.doi.org/10.1016/J.IJID.2020.03.061